Philip R. Dormitzer
Affiliations: | Harvard University, Cambridge, MA, United States |
Area:
Microbiology Biology, Molecular Biology, General BiophysicsGoogle:
"Philip Dormitzer"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dieussaert I, Hyung Kim J, Luik S, et al. (2024) RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. The New England Journal of Medicine. 390: 1009-1021 |
| Che Y, Gribenko AV, Song X, et al. (2023) Rational Design of a Highly Immunogenic Prefusion-Stabilized F Glycoprotein Antigen for a Respiratory Syncytial Virus Vaccine. Science Translational Medicine. eade6422 |
| Tabata T, Petitt M, Li J, et al. (2022) Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. Vaccines. 10 |
| Schmoele-Thoma B, Zareba AM, Jiang Q, et al. (2022) Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. The New England Journal of Medicine. 386: 2377-2386 |
| Baber J, Arya M, Moodley Y, et al. (2022) A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults. The Journal of Infectious Diseases |
| Simões EAF, Center KJ, Tita ATN, et al. (2022) Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. The New England Journal of Medicine. 386: 1615-1626 |
| Li J, Wellnitz S, Chi XS, et al. (2022) Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses. The Journal of Infectious Diseases |
| Liu J, Liu Y, Xia H, et al. (2022) BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines. 7: 41 |
| Moreira ED, Kitchin N, Xu X, et al. (2022) Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. The New England Journal of Medicine |
| Walsh EE, Falsey AR, Scott DA, et al. (2021) A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. The Journal of Infectious Diseases |